Chromophore-modified bis-naphthalimides: Synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones

Journal of Medicinal Chemistry

Volumn 40, Issue 4, 1997, Pages 449-454

  Brana M F ^a   Castellano, J M ^b   Perron, D ^c   Maher, C ^c   Conlon, D ^c   Bousquet, P F ^c   George, J ^c   Qian, X D ^c   Robinson, S P ^c  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b Laboratorios Knoll SA   (Spain)

^c BASF Bioresearch Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; N,N' BIS[2 (1,2 DIHYDRO 1,3 DIOXO 3H DIBENZ[DE,H]ISOQUINOLIN 2 YL)ETHYL] 1,3 PROPANEDIAMINE; N,N' BIS[2 (1,2 DIHYDRO 1,3 DIOXO 3H DIBENZ[DE,H]ISOQUINOLIN 2 YL)ETHYL]PERHYDROPYRIMIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CHROMATOPHORE; DRUG CYTOTOXICITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; MOUSE; NONHUMAN; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME;

1-NAPHTHYLAMINE; AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA, SUPERHELICAL; HUMANS; ISOQUINOLINES; MICE; TUMOR CELLS, CULTURED;

EID: 0031055564     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960295k     Document Type: Article

References (26)

1. 1H NMR study of binding mode and kinetics, J. Med. Chem. 1984, 27, 450-465.
2. Schneider, E.; Hsiang, Y. H.; Liu, L. F. DNA topoisomerases as anticancer drugs targets. Advances in Pharmacology. Academic Press: San Diego, 1990; Vol. 21, pp 149-183.
3. Braña, M. F.; Castellano, J. M.; Roldan, C. M.; Santos, A.; Vazquez, D.; Jimenez, A. Synthesis and mode of action of a new series of imide derivatives of 3-nitro-1,8-naphthalic acid. Cancer Chemother. Pharmacol. 1980, 4, 61-66.
4. Brana, M. F.; Sanz, A. M.; Castellano, J. M.; Roldan, C. M.; Roldan, C. Synthesis and cytostatic activity of benz[d,e]isoquinoline-1,3-diones. Structure-activity relationships. Eur. J. Med. Chem. 1981, 16, 207-212.
5. Waring, M. J.; Gonzalez, A.; Jimenez, A.; Vazquez, D. Intercalative binding to DNA of antitumor drugs derived from 3-nitro-1,8-naphthalic acid. Nucleic Acids Res. 1979, 7, 217-230.
6. Wakelin, L. P. G.; Waring, M. J. DNA intercalating agents. In Comprehensive Medicinal Chemistry; Sammes, P. G., Ed.; Pergamon Press: Oxford, 1990; Vol. 2, pp 702-724.
7. Malviya, V. K.; Liu, P. Y.; Alberts, D. S.; Surwit, E. A.; Craig, J. B.; Hanningan, E. V. Evaluation of Amonafide in cervical cancer, phase II. Am. J. Clin. Oncol. 1992, 15, 41-44 and references cited therein.
8. Rosell, R.; Carles, J.; Abad, A.; Ribelles, N.; Barnadas, A.; Benavides, A.; Martin, M. Phase I study of Mitonafide in 120 h continuous infusion in non small cell lung cancer. Invest. New Drugs 1992, 10, 171-175.
9. Llombart, M.; Poveda, A.; Forner, E.; Martos, C. F.; Gaspar, C.; Muñoz, M.; Olmos, T.; Ruiz, A.; Soriano, V.; Benavides, A.; Martin, M.; Schlick, E.; Guillem, V. Phase I study of Mitonafide in solid tumors. Invest. New Drugs 1992, 10, 177-181.
10. Scheithauer, W.; Kornek, G.; Haider, K.; Depisch, D. Amonafide in metastatic colorectal carcinoma. Eur. J. Cancer 1990, 26, 923-924.
11. Kornek, G.; Raderer, M.; Depisch, D.; Haider, K.; Fazeny, B.; Dittrich, C.; Scheithauer, W. Amonafide as first-line chemotherapy for metastatic breast cancer. Eur. J. Cancer 1994, 30A, 398-400.
12. Craig, J.; Crawford, E. Phase II trial of amonafide in advanced prostate cancer. Proc. Am. Soc. Clin. Oncol. 1989, 8, 147.
13. Allen, S. L.; Budman, D. R.; Fusco, D.; Kolitz, J.; Kreis, W.; Schulman, P.; Schuster, M.; Demarco, L.; Marsh, J.; Haptas, K.; Fischkoff, S. Phase I trial of Amonafide + cytosine arabinoside for poor risk acute leukemias. Proc. Am. Soc. Clin. Oncol. 1994, 35, 225.
14. Sami, S. M.; Dorr, R. T.; Alberts, D. S.; Remers, W. A. 2-Substituted 1,2-Dihydro-3H-dibenz[de,h]isoquinoline-1,3-diones. A New Class of Anti-tumor Agent. J. Med. Chem. 1993, 36, 765-770.
15. Sami, S. M.; Dorr, R. T.; Solyion, A. M.; Alberts, D. S.; Remers, W. A. Amino-Substituted 2-[2′-(Dimethylamino)ethyl]-1,2-Dihydro-3H-dibenz[de,h]isoquinoline-1,3- diones. Synthesis, Antitumor Activity and Quantitative Structure-Activity Relationship. J. Med. Chem. 1995, 38, 983-993.
16. Braña, M. F.; Castellano, J. M.; Moran, M.; Perez de Vega, M. J.; Romerdahl, C. A.; Qian, X. D.; Bousquet, P.; Emling, F.; Schlick, E.; Keilhauer, G. Bis-naphthalimides: a New Class of Antitumor Agents. Anti-Cancer Drug Des. 1993, 8, 257-268.
17. Braña, M. F.; Castellano, J. M.; Moran, M.; Perez de Vega, M. J.; Qian, X. D.; Romerdahl, C. A.; Keilhauer, G. Bis-naphthalimides 2: Synthesis and Biological Activity of 5,6-Acenaphthalimidoalkyl-1,8-naphthalimidoalkylamines. Eur. J. Med. Chem. 1995, 30, 235-239.
18. Braña, M. F.; Castellano, J. M.; Moran, M.; Perez de Vega, M. J.; Perron, D.; Conlon, D.; Bousquet, P.; Romerdahl, C. A.; Robinson, S. Bis-naphthalimides 3: Synthesis and anti-tumor activity of N,Ń-Bis[2-(1,8-naphthalimido)ethyl]alkanediamines. Anti-Cancer Drug Des., in press.
19. Bousquet, P.; Braña, M. F.; Conlon, D.; Fitgerald, K. M.; Perron, D.; Cocchiaro, C.; Miller, R.; Moran, M.; George, J.; Qian, X. D.; Keilhauer, G.; Romerhdal, C. A. Preclinical Evaluation of LU 79553: A Novel Bis-naphthalimide with Potent Antitumor Activity. Cancer Res. 1995, 55, 1176-1180.
20. Bergmann, E. D.; Ikan, R. A Synthesis of Aceanthrene. J. Org. Chem. 1958, 23, 907-908.
21. Israel, M.; Modest, E. J. Synthesis of Aminoethyl Derivatives of α,ω-Alkylenediamines and Structure Activity Relationship for the Polyamine Bovine Plasma Amine Oxidase System. J. Med. Chem. 1971, 14, 1042-1047.
22. Akock, N. W.; Moore, P.; Omar, H. A.; Reader, C. J. Nickel(II), Copper(II), and Zinc(II) Complexes of Pentaazamacrocyclic Ligands, Crystal and Molecular Structure of 3,6,9,12-Tetramethyl-3,6,9,12,18-pentaazabicyclo[12.3.1]octadeca-1(18),14,16- trienezinc(II) Perchlorate. J. Chem. Soc. 1987, 2643-2648.
23. Farrar, W. V. Formaldehyde-amide Reactions. Rec. Chem. Prog. 1968, 29, 85-101.
24. Sahai, B. M.; Kaplan, J. G. A quantitative decatenation assay for Type II topoisomerases. Anal. Biochem. 1986, 156, 364-379.
25. Chen, A. Y.; Yu, C.; Bodley, A.; Peng, L. F.; Liu, L. F. A new mammalian DNA topoisomerase I poison Hoechst 33342: cytotoxicity and drug resistance in human cell cultures. Cancer Res. 1993, 53, 1332-1337.
26. Rose, W. C.; Schurig, J. E.; Huffalen, J. B.; Bradner, W. T. Experimental antitumor activity and toxicity of a new chemotherapeutic agent BBM928A. Cancer Res. 1983, 43, 1504-1510.